In 25, Hony Capital, a subsidiary of Legend Holdings, invested 21 million yuan and held 31% of the shares in simcere. On April 2th, 27, simcere successfully landed on the new york Stock Exchange, raising 261 million US dollars with the stock code SCR, becoming the first chemical and biological drug company listed on the NYSE in China. In 29, simcere achieved a sales income of 1.85 billion yuan, paid 341 million yuan in state taxes, and achieved a net profit of 12 million yuan.

At present, simcere has a strong product portfolio of more than 45 kinds of drugs, focusing on the treatment of tumors, cardiovascular and cerebrovascular diseases, infections and other diseases. We have the brand of "Re-forest" with market leading position, and enjoy the "China Famous Trademark" with separate pricing policy; "Bicun", the first anti-stroke drug to enter the China market, is the first new free radical scavenger with clear action mechanism; Endo, an innovative anti-cancer drug of recombinant human endostatin, has patents in China and the United States, and won the 1th China Patent Gold Award and the second prize of the 28 National Technological Invention Award; And three other brand drugs with annual sales of more than 7 million or over 1 million: Yingtaiqing, Biqi and Anqi; Among them, Yingtaiqing is another "well-known trademark of China", and it became the promotion partner of NBA China in 29. Biapenem for Anxin injection, which was first listed in China in 28, provides a new treatment choice for patients with moderate and severe infections in China. In 29, antihypertensive drugs were introduced into the market, and they made great strides in the field of cardiovascular treatment. In the same year, simcere successively cooperated with two biopharmaceutical companies, Shanghai Saijin and Jiangsu Yanchang, to further enter the field of antibodies and vaccines. First, more brand products with strong market competitiveness are in the pipeline. Simcere has an extensive distribution network and professional marketing team in China, with nearly 2, salespeople and nearly 1 strategic partners, 8% of whom have medical degrees. In China, Xiansheng has more than 1,5 dealers. Our products are sold to more than 4, hospitals in China and 7, pharmacies. Every year, there are thousands of academic conferences hosted, hosted and co-organized by simcere, and hundreds of academic materials and papers are compiled, so tens of thousands of doctors learn, communicate and improve better.

simcere Xiansheng Pharmaceutical Research Institute was established in 24, with several technical platforms for the research of chemicals and biological drugs. At present, 89 China invention patents have been applied for or obtained, and 1 first and exclusive varieties have been successfully developed and listed. The project of "Re-Chang Tablet of a New Drug" won the second prize of National Science and Technology Progress Award. In 23, with the approval of the Ministry of Personnel, Post-Doctoral Research Center was established, and 11 postdoctoral fellows entered the station successively. In January 26, simcere and Tsinghua University established a "Joint Laboratory for Innovative Drugs", and at the same time, they are cooperating with Nanjing University, China Pharmaceutical University, Shanghai Institute of Pharmacology of China Academy of Sciences, Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences, Edwin Laboratory of the United States, Epitomics Company, OSI and other units on new drug research and development. At the end of 26, the modern R&D center of Xiansheng Pharmaceutical Research Institute with an area of over 5, square meters was officially opened, and the R&D base of Shanghai International Medical Park started construction at the end of 28. The layout of simcere's R&D laboratories in Nanjing, Beijing and Shanghai has taken shape. In October 29, the second phase project of Xiansheng Pharmaceutical Research Institute, with larger and more advanced facilities and a total investment of nearly 3 million yuan, officially broke ground.

The research and development of new drugs in simcere is market-oriented, and focuses on innovative drugs with broad market potential or brand generic drugs first developed in China market. We focus our research and development efforts on the treatment of diseases with high morbidity or mortality and more effective drug demand, such as cancer, stroke, osteoporosis and infectious diseases. In recent years, simcere has introduced a series of brand generic drugs or innovative drugs, such as Zhongren Fuan, Jiebaishu and Anxin, which are the first to enter the market, filling many domestic gaps. At present, more than 1 research projects in simcere are at different stages of research and development.

In the future, simcere's corporate goal is to become a leader in innovative drug development in China and create revolutionary drugs in major challenges. We are gathering more strength to seek and provide more effective drugs for patients, so that employees can be proud of it and win the respect of customers and society.